Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer

被引:33
作者
Inoue, Kazushi [1 ]
Fry, Elizabeth A. [1 ]
机构
[1] Wake Forest Univ Hlth Sci, Dept Pathol, Med Ctr Blvd, Winston Salem, NC 27157 USA
关键词
splicing; oncogene; tumor suppressor gene; cancer; prognosis; DMP1 (DMTF1); ARF; MDM2; p53; INDEPENDENT PROGNOSTIC MARKER; TRANSCRIPTION FACTOR DMP1; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; P53; ISOFORMS; BREAST-CANCER; GENOMIC ORGANIZATION; GENE-EXPRESSION; DOWN-REGULATION; CRITICAL ROLES;
D O I
10.1002/ijc.30003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Alternative splicing (AS) of mRNA precursors is a ubiquitous mechanism for generating numerous transcripts with different activities from one genomic locus in mammalian cells. The gene products from a single locus can thus have similar, dominant-negative or even opposing functions. Aberrant AS has been found in cancer to express proteins that promote cell growth, local invasion and metastasis. This review will focus on the aberrant splicing of tumor suppressor/oncogenes that belong to the DMP1-ARF-MDM2-p53 pathway. Our recent study shows that the DMP1 locus generates both tumor-suppressive DMP1 (p53-dependent) and oncogenic DMP1 (p53-independent) splice variants, and the DMP1/ ratio increases with neoplastic transformation of breast epithelial cells. This process is associated with high DMP1 protein expression and shorter survival of breast cancer (BC) patients. Accumulating pieces of evidence show that ARF is frequently inactivated by aberrant splicing in human cancers, demonstrating its involvement in human malignancies. Splice variants from the MDM2 locus promote cell growth in culture and accelerate tumorigenesis in vivo. Human cancers expressing these splice variants are associated with advanced stage/metastasis, and thus have negative clinical impacts. Although they lack most of the p53-binding domain, their activities are mostly dependent on p53 since they bind to wild-type MDM2. The p53 locus produces splice isoforms that have either favorable (/ at the C-terminus) or negative impact (40, 133 at the N-terminus) on patients' survival. As the oncogenic AS products from these loci are expressed only in cancer cells, they may eventually become targets for molecular therapies.
引用
收藏
页码:33 / 41
页数:9
相关论文
共 88 条
  • [51] The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
    Manfredi, James J.
    [J]. GENES & DEVELOPMENT, 2010, 24 (15) : 1580 - 1589
  • [52] Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response
    Marcel, V.
    Fernandes, K.
    Terrier, O.
    Lane, D. P.
    Bourdon, J-C
    [J]. CELL DEATH AND DIFFERENTIATION, 2014, 21 (09) : 1377 - 1387
  • [53] p53 regulates the transcription of its Δ133p53 isoform through specific response elements contained within the TP53 P2 internal promoter
    Marcel, V.
    Vijayakumar, V.
    Fernandez-Cuesta, L.
    Hafsi, H.
    Sagne, C.
    Hautefeuille, A.
    Olivier, M.
    Hainaut, P.
    [J]. ONCOGENE, 2010, 29 (18) : 2691 - 2700
  • [54] p53 isoforms - A conspiracy to kidnap p53 tumor suppressor activity?
    Marcel, V.
    Hainaut, P.
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2009, 66 (03) : 391 - 406
  • [55] Regulation of the p53 response and its relationship to cancer
    Meek, David W.
    [J]. BIOCHEMICAL JOURNAL, 2015, 469 : 325 - 346
  • [56] The expanding universe of p53 targets
    Menendez, Daniel
    Inga, Alberto
    Resnick, Michael A.
    [J]. NATURE REVIEWS CANCER, 2009, 9 (10) : 724 - 737
  • [57] The MDM2 gene amplification database
    Momand, J
    Jung, D
    Wilczynski, S
    Niland, J
    [J]. NUCLEIC ACIDS RESEARCH, 1998, 26 (15) : 3453 - 3459
  • [58] Sarcomas in TP53 Germline Mutation Carriers A Review of the IARC TP53 Database
    Ognjanovic, Simona
    Olivier, Magali
    Bergemann, Tracy L.
    Hainaut, Pierre
    [J]. CANCER, 2012, 118 (05) : 1387 - 1396
  • [59] Endogenous Human MDM2-C Is Highly Expressed in Human Cancers and Functions as a p53-Independent Growth Activator
    Okoro, Danielle R.
    Arva, Nicoleta
    Gao, Chong
    Polotskaia, Alla
    Puente, Cindy
    Rosso, Melissa
    Bargonetti, Jill
    [J]. PLOS ONE, 2013, 8 (10):
  • [60] Okoro Danielle R, 2012, Genes Cancer, V3, P311, DOI 10.1177/1947601912455323